MX2015007945A - Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. - Google Patents

Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.

Info

Publication number
MX2015007945A
MX2015007945A MX2015007945A MX2015007945A MX2015007945A MX 2015007945 A MX2015007945 A MX 2015007945A MX 2015007945 A MX2015007945 A MX 2015007945A MX 2015007945 A MX2015007945 A MX 2015007945A MX 2015007945 A MX2015007945 A MX 2015007945A
Authority
MX
Mexico
Prior art keywords
treatment
conditions
liver diseases
methods
diamidines
Prior art date
Application number
MX2015007945A
Other languages
English (en)
Spanish (es)
Inventor
François Ravenelle
Pierre Falardeau
Patrick Colin
Original Assignee
Verlyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verlyx Pharma Inc filed Critical Verlyx Pharma Inc
Publication of MX2015007945A publication Critical patent/MX2015007945A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
MX2015007945A 2012-12-21 2013-12-20 Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. MX2015007945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745011P 2012-12-21 2012-12-21
PCT/CA2013/051003 WO2014094176A1 (en) 2012-12-21 2013-12-20 Uses and methods for the treatment of liver diseases or conditions

Publications (1)

Publication Number Publication Date
MX2015007945A true MX2015007945A (es) 2016-02-16

Family

ID=50977490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007945A MX2015007945A (es) 2012-12-21 2013-12-20 Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.

Country Status (12)

Country Link
US (2) US9375411B2 (enExample)
EP (1) EP2934501A4 (enExample)
JP (1) JP6370801B2 (enExample)
KR (1) KR20150126595A (enExample)
CN (1) CN104968340A (enExample)
AU (1) AU2013362755B2 (enExample)
BR (1) BR112015014836A2 (enExample)
CA (1) CA2894466A1 (enExample)
HK (1) HK1216721A1 (enExample)
MX (1) MX2015007945A (enExample)
RU (1) RU2015126505A (enExample)
WO (1) WO2014094176A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225686A (zh) * 2017-08-15 2020-06-02 普罗根尼蒂公司 使用可摄入装置释放免疫调节剂治疗炎性疾病
JP7153734B2 (ja) 2017-11-16 2022-10-14 モンドレックス・インコーポレーテッド モノアミジン及びジアミジンのエンド－エキソヌクレアーゼ阻害剤とエンド－エキソヌクレアーゼ活性を阻害する方法
CN110478340A (zh) * 2018-05-14 2019-11-22 复旦大学 喷他嘧啶羟乙基磺酸盐在制备肝癌药物方面的应用
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA388674A (en) * 1940-05-14 The B. F. Goodrich Company Brake structure
GB1288376A (enExample) 1968-10-29 1972-09-06
DE2833135A1 (de) 1978-07-28 1980-02-07 Henkel Kgaa Verwendung von substituierten oligocarbamidinen als mikrobistatika sowie diese enthaltende antimikrobielle mittel
US5204113A (en) 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5084480A (en) 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US4853416A (en) 1988-04-25 1989-08-01 Fisons Corporation Solutions of pentamidine
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JPH08333324A (ja) 1995-06-08 1996-12-17 Terumo Corp ベンゼン誘導体およびそれを含有する医薬製剤
JP3540457B2 (ja) 1995-09-11 2004-07-07 テルモ株式会社 抗血栓性を賦与した医療用基材
AU762523C (en) 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
US7884090B2 (en) 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US7115665B1 (en) 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
CA2459793A1 (en) 2001-09-07 2003-08-28 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
WO2003092616A2 (en) * 2002-05-01 2003-11-13 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050054708A1 (en) 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2005089738A2 (en) 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
WO2007001455A2 (en) 2004-11-12 2007-01-04 Mediquest Therapeutics, Inc. Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
US7199267B1 (en) 2005-10-21 2007-04-03 Mediquest Therapeutics, Inc. Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
US20070197658A1 (en) 2006-02-22 2007-08-23 David Sunil A Polyamines and their use as antibacterial and sensitizing agents
US20080226596A1 (en) 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
DE102008007426A1 (de) 2008-02-01 2009-08-06 Rheinische Friedrich-Wilhelms-Universität Bonn Unbenetzbare Oberflächen
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
US8436049B2 (en) 2008-02-21 2013-05-07 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Uses of pentamidine and related compounds
JP2012525371A (ja) * 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
WO2011035225A1 (en) 2009-09-21 2011-03-24 President And Fellows Of Harvard College Synergistic combination therapy
US20130244963A1 (en) 2010-09-30 2013-09-19 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
SI2550963T1 (sl) * 2011-07-25 2017-05-31 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Estri amidoksim karboksilne kisline pentamidina kot predzdravila in njihova uporaba kot zdravila
WO2014009592A1 (en) * 2012-07-11 2014-01-16 Waterbox Oy Apparatus for providing rotating movement

Also Published As

Publication number Publication date
JP2016503035A (ja) 2016-02-01
KR20150126595A (ko) 2015-11-12
AU2013362755A1 (en) 2015-07-02
EP2934501A4 (en) 2016-06-01
HK1216721A1 (zh) 2016-12-02
EP2934501A1 (en) 2015-10-28
JP6370801B2 (ja) 2018-08-08
US20160287535A1 (en) 2016-10-06
RU2015126505A (ru) 2017-01-27
US9375411B2 (en) 2016-06-28
US9827211B2 (en) 2017-11-28
AU2013362755B2 (en) 2018-09-13
WO2014094176A1 (en) 2014-06-26
CN104968340A (zh) 2015-10-07
CA2894466A1 (en) 2014-06-26
BR112015014836A2 (pt) 2017-07-11
US20150297540A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
IN2015DN01156A (enExample)
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014028591A3 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12016500024A1 (en) Bromodomain inhibitor
IN2014MN02652A (enExample)
IN2014MN02657A (enExample)
IN2014DN10670A (enExample)
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
IN2014DN09434A (enExample)
MY199131A (en) Human plasma kallikrein inhibitors
HK1216175A1 (zh) 治療性化合物和組合物
LT2726511T (lt) Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui
MX2020001602A (es) Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
IN2014DN09173A (enExample)
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
IN2015DN01119A (enExample)
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016502352A1 (en) Pharmaceutical composition